CSF-ctDNA was detected in 59% of cases and showed high concordance (84%) with tumor mutations. Lower variant allelic frequency in CSF-ctDNA was associated with significantly worse survival outcomes.
Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022 Effective diagnosis, prognostication, ...
In a recent JAMA Network Open study, researchers compare Klotho protein levels within both cerebrospinal fluid (CSF) and plasma samples of healthy individuals and patients diagnosed with different ...